Onyx Frontier DES Assists Treatment of Cardiac Artery Blockages

To enhance the care for patients with coronary artery disease, Medtronic created the Onyx Frontier DES, aiming to assist doctors in medicating cardiac artery blockages- thus boosting results for patients by enhancing doctor’s ability to deliver treatment without reducing the stent’s radial strength.

The FDA announced its decision to sanction improvements to Resolute Onyx’s distribution system and its marketing as Onyx Frontier in May of this year, allowing Medtronic to release the improved device on the American market. They have also received a CE mark, therefore also allowing the firm access to the European market.

Medtronic’s coronary and renal denervation businesses saw a recent decline in revenues, contributing to the coronary and peripheral vascular division’s revenue reduction which stood at 7%. The effect of the pandemic on percutaneous coronary interventions (PCI) was named as the cause of the decline.

Onyx Frontier will be sold by Medtronic, with left main PCI named of its approved uses. Due to the similar functionality of Onyx Frontier and Resolute Onyx, Frontier has been transferred Resolute’s data, so the only comparable variance is bench testing data available that looks at five or seven of each stent.

Medtronic’s leader of the coronary and renal denervation sector, Jason Weidman, explained: “The Onyx Frontier DES launch demonstrates our commitment to interventional cardiologists by providing best-in-class products. Following our launch in the U.S., we’re thrilled to provide hospitals across western Europe and the globe with the Onyx Frontier DES.”

© Copyright 2010-2021 Zenopa LTD. All Rights Reserved.